The Latest Breaking News on Pharma

Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.

The U.S. Drug Enforcement Administration has stripped one of the nation’s largest pharmaceutical distributors of its license to sell highly addictive painkillers after determining it failed to flag thousands of suspicious, high-volume orders at the height of the opioid crisis

Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders.

Banks Bourne, sole owner of Tanner Pharma in North Carolina, took sum from Tanner’s UK arm, records show

Medtronic is facing sluggish sales growth, is in the midst of deep cost-cutting and started ongoing global layoffs in April. It's also spinning off businesses with weaker profit margins.

McKesson is Wednesday's IBD Stock Of The Day. Drug distributors are hot and MCK stock is consolidating following a strong quarterly report.

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore, investors could look to avoid fundamentally weak biotech stocks Bicycle Therapeutics (BCYC), CorMedix (CRMD), and 22nd Century Group (XXII).…

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

A House panel advanced a 2024 budget bill that would block the ability to access the abortion drug via telehealth

The U.S. Drug Enforcement Administration has allowed one of the nation’s largest drug distributors to keep shipping addictive painkillers for nearly four years despite a judge’s recommendation to strip its license for turning a blind eye to thousands of suspicious opioid orders

PTC stock plummeted Wednesday and gave its closest rival a boost after the company's treatment for a neurological disorder flunked.